DRG Market Assessment reports

Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress…

Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…

Market Outlook Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular…

Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…

Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…

Treatment of heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of evidence from clinical trials that support the use of all standard-of-care therapies for CHF…

Market Outlook Elevated serum potassium, commonly known as hyperkalemia, is a condition common in patients with decreased renal function and heart failure and is often exacerbated by those…

First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and  an oral diuretic. Second- or third-line treatments are…

The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity…

Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. Second- or third-line treatments is…

From disease basics to insightful analysis of market dynamics, Heart Failure | Disease Landscape & Forecast | G7 provides comprehensive disease coverage addressing critical aspects of the heart…